Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled, Blinded, Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and PK/PD Profiles of RAB001 for Injection in Patients With Early-stage Non-traumatic Osteonecrosis Caused by Long-term Glucocorticoid Use.（LLP2A-Alendronate）

NCT07471880 is registered in ClinicalTrials.gov with ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. as lead sponsor.

NCT NCT07471880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07471880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled, Blinded, Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and PK/PD Profiles of RAB001 for Injection in Patients With Early-stage Non-traumatic Osteonecrosis Caused by Long-term Glucocorticoid Use.（LLP2A-Alendronate）
Lead sponsor
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 24, 2024
Completion date
February 28, 2027
Enrollment
161 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteonecrosis, osteonecrosis of the femoral head